INTRODUCTION
Highly active antiretroviral therapy (HAART) combines various protease inhibitors (PI), nucleoside analogue reverse transcriptase inhibitors (NRTI) and non-nucleoside analogue reverse transcriptase inhibitors (NNRTI). Whereas HAART efficiently suppresses HIV replication, long-term treatment of HIV-infected patients has been associated with a lipodystrophic syndrome and metabolic complications, one of the most common being hypertriglyceridemia (6). The HAART-associated lipodystrophy is characterised by peripheral fat wasting in the face and limbs and accumulation of visceral fat, breast hypertrophy and cervical fat-pads (buffalo hump) (7-9). Metabolic complications are preferentially associated to PI and appear much more rapidly than lipodystrophy (20). It is not known whether the latter is a long-term consequence of the metabolic disorder or whether it corresponds to distinct molecular mechanisms. Because of the lack of pertinent experimental model, the pathogenesis and physiopathological mechanisms by which PI/NRTI/NNRTI cause HAARTassociated lipodystrophy and metabolic disorders remain to be elucidated.
PI/NRTI/NNRTI can interfere with adipocyte differentiation and adipocyte-specific gene expression (16, 18, 22, (26) (27) (28) (29) . However the reported effects are very variable, positive or negative, depending on the molecule and on the experimental model studied. Furthermore, these cellular studies do not explain why HAART leads, in one case, to peripheral lipoatrophy and, in the other case, to abdominal hypertrophy of the adipose tissue. Short-term treatment (10 days) of mice evidenced a hyperlipidemic effect of the PI ritonavir (21). This effect correlated with the activation of SREBP-1c in liver and white adipose tissues (WAT).
Because HAART is the association of several drugs, it is impossible to discriminate the precise contribution of each antiretroviral compound. In order to get insights into the physiopathological mechanisms underlying the lipodystrophy syndrome we long-term treated
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Pharmacokinetic analysis
C57BL/6J male mice were treated daily with Atazanavir or Lopinavir/Ritonavir for 3 days. The fourth day, mice were anaesthetized with pentobarbital (9mg/mouse) and 500µl of blood samples were collected from the retroorbitary sinus at various times after the last gavage. PIs plasma concentrations were determined by HPLC using a reverse phase column and a DAD detector; the limit of quantification was 50 ng/ml. AUC in plasma were estimated by using a non compartimental analysis model (Winonlin 3.2 software).
Collection of tissues and serum analysis
Following blood sampling, serum was isolated by centrifugation and immediately stored at -80°C until analysis. Inguinal white adipose tissue, epididymal white adipose tissue, interscapular brown adipose tissue (BAT) and liver were excised and weighed. For RNA isolation samples of epididymal and inguinal white adipose tissues of left side were placed on ice and immediately homogenized with TRIZOL reagent (Invitrogen Life Technologies).
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Quantification of triglycerides was performed using the Triglycerides 100 biochemical kit (ABX diagnostics, Montpellier, France). Glycemia was determined by Accu-Check active bands (Roche Diagnostics, Mannheim, Germany).
Adipose tissue histology.
The epididymal and inguinal white adipose tissue of right side were formalin-fixed and paraffin-embedded. The sections were stained with hematoxylin-eosin-safranin for light microscopic examination.
Analysis of mRNA levels by Real-Time Quantitative PCR
Total RNA was prepared using Trizol reagent (Invitrogen, Carlsbad, CA) and gene expression analysis was performed with the ABI Prism 7000 (Applied Biosystem) and SYBR Green Reagents (Eurogentec, Seraing, Belgium) as already described (2) . Briefly, cDNAs
were synthesized from 2µg of total RNA using Superscript II reverse transcriptase 
RESULTS
In order to set up an experimental model to study the HAART-associated lipodystrophy, control mice were compared to mice receiving two long-term IP treatments: the classical association of lopinavir/ritonavir (LPV/r), strongly involved in HAART, and the new compound atazanavir (ATV) which induces rare metabolic disorders in patients (12, 19) .
Pharmacokinetic analysis
Pharmacokinetic analysis was performed to determine the dose regimen necessary to obtain in mice circulating drug concentrations similar to human therapeutic levels. Two lopinavir/ritonavir (LPV/r) doses, 200/50 and 400/100mg/kg (15 to 30 fold the human dose),
were given daily to animals by oral gavage. The fourth treatment day, LPV and RTV concentrations were determined at 0, 2, 4, 6, 8 and 12hr after the last gavages. In humans the areas under the curve (AUC) value of lopinavir, on a 12 hours period, is comprised between 52 and 76µg.h/ml (10) (14) . Our results show that lopinavir was eliminated rapidly in mice, the 200mg/kg/day dose giving impregnation similar to human dosages, with 95µg.h/ml AUC, whereas impregnation by the 400mg/kg/day dose was four fold higher, with 255µg.h/ml AUC ( Figure 1 ). Ritonavir was also eliminated rapidly and its concentration peaked at 2µg/ml, for the 50mg/kg dose, which is similar to human dosages (data not shown). Long-term treatment at the400/100mg/kg/day dose appeared highly toxic, leading to death of most of the mice after few weeks (data not shown). In the case of atazanavir, we also chose a concentration 15 fold higher than in humans and found that the 90mg/kg/day dose gave a peak of circulating concentration after 1h of 12µg/ml, which decreased rapidly (data not shown). The calculated AUC is 32.7µg.h/ml, giving impregnation similar to human dosages (whose AUC is 28µg.h/ml). Our results show that half-life and steady-state levels of these molecules are shorter in mice as in humans. An important pharmaceutical parameter is the fraction of drugs results show no significant differences between human and mice for these molecules.
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Therefore we postulate that the impregnation and the proportion of active molecules we obtained in mice are comparable to that reached in human therapy.
Lopinavir/ritonavir (LPV/r) induces hypertriglyceridemia in mice
Retro-orbital blood sampling was performed on control C57Bl6J male mice and mice treated daily with three different doses of LPV/r (100/25, 200/50 and 300/75mg/kg/day) for two weeks. Samples were analysed for glucose and triglyceride contents. The three LPV/r treatments induced hypertriglyceridemia in mice (2.2, 5.1 and 3.8 fold the triglyceride concentration of control mice, respectively) after two weeks (Figure 2A ). This effect was stable over the time and persisted in eight weeks-treated animals ( Figure 2B ). Glycemia was measured in these animals and no change was induced by the various LPV/r treatments ( Figure 2C for the 200/50mg/kg/day dose and data not shown). Our results reproduce the dyslipidemia syndrome associated with HAART in humans and the observation that these effects are much more frequent and substantial than changes in glucose levels (25). The 200/50mg/kg/day dose was used in the following experiments, a dose which did not appeared toxic and induced reproducible hypertriglyceridemia.
We then analysed the metabolic parameters of mice treated for 8 weeks either with LPV/r (200/50mg/day) or atazanavir (ATV) (90mg/kg/day) compared with the control treated mice. Whereas no change was observed in glycemia (data not shown), only the LPV/r treatment induced hypertriglyceridemia (2.5 fold the triglyceride concentration of control or ATV-treated mice), confirming the absence of metabolic effect of ATV ( Figure 2D) . In preliminary experiments, 6 or 8 weeks old mice were treated for height weeks with LPV/r at 200/50mg/kg/day. At those ages mice are still growing and, over a period of 8 weeks, the weight of control mice went up from 20 to 27g and from 25 to more than 30g, respectively. In those cases, LPV/r treatment had a marked inhibitory effect on growth; the weight of treated mice did not increase or increased much more slowly than in control mice ( Figure 3A) . This effect of the 200/50mg/kg LPV/r dose on young mice is probably related to the relatively toxic effect of LPV/r, already observed at higher doses. We then, performed the experiments by starting with 10 weeks old mice and ATV-treated mice were included in those experiments. No effect on weight was noticed between the three groups of mice, their starting weight was around 30g +/-2 for all the mice, and this value did not change significantly during the treatments ( Figures 3B and 4) . After 8 weeks, mice were sacrificed, and various tissues were carefully dissected and weighed. Two different groups of mice were treated in the same conditions, whose results are presented in figure 4A . Compared to controls, the weight of the peripheral inguinal adipose depot was significantly reduced by 25% by the LPV/r treatment. A representative lipoatrophic effect of the LPV/r treatment on peripheral inguinal adipose depot is presented in figure 4B . No significant change was observed in the size of adipocytes of LPV/r treated animals, suggesting that the lipoatrophic effect was due to a remodelling of the tissue rather than a cellular effect. By contrast, the epididymal fat depot and the brown adipose tissues were not significantly modified ( Figure 4A ). Compared to control mice, ATV treatment did not induce significant changes in any of the tissues we investigated ( Figure 4A ). 
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DISCUSSION
In order to get insights into the physiopathological mechanisms underlying the lipodystrophy syndrome we treated mice with protease inhibitors for long periods. We found that the lopinavir/ritonavir association induces hypertriglyceridemia and reduces specifically peripheral inguinal WAT depots of 10 weeks-old mice treated for 8 weeks. The metabolic disorder observed in our animal model reproduces the dyslipidemia observed in the human disease. The HAART-associated lipodystrophic syndrome in humans is also reproduced in mice, but only partially. Particularly, the peripheral lipoatrophy is effectively detected in mice at the level of inguinal WAT depots, whereas other tissues are not affected. However, this effect on mice does not match completely the observations reported in humans, for example we did not notice any change at the level of the other WAT depots.
In a recently published study (11) the authors analysed the effects of a ritonavir longterm treatment on 5 weeks-old mice. They found that the drug induces a general lipoatrophy and exerts a potent blocking effect on the general growth of the animals. Similarly to their data, we also noticed that drug treatment of young animals, while they are still growing, led to potent inhibition of their growth. Furthermore, we observed that higher doses led to a rapid death of the animals. Therefore, it is possible that, in young animals, the observed effects may be related to a toxic unspecific effect rather than a lipodystrophic potential. By contrast, starting the treatment with 10 weeks-old adult animals did not affect their growth. Therefore, it is likely that treating animals after puberty, when growth has slowed down or stopped, is more relevant to HAART-associated lipodystrophy described in adult humans.
Importantly, lopinavir/ritonavir (LPV/r) reduces the peripheral white adipose depot in long-term treated mice without affecting the other fat depots. Compared to visceral adipose tissue, peripheral/subcutaneous adipose tissue display important differences in their biological
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Interestingly, potent activators of peroxisome proliferator-activated receptor γ (PPARγ), such as thiazolidinedione (TZD), increase adipocyte differentiation of subcutaneous preadipocytes but have no effect on adipocyte differentiation of visceral precursors (1). We found no effect of LPV/r on PPARγ expression, suggesting that the reduction of peripheral WAT by LPV/r is not due to a PPARγ downregulation. However, one possibility to be tested is that TZD could counteract the LPV/r-induced reduction of peripheral WAT by increasing adipogenesis in this tissue.
We found that the reduction in peripheral WAT depot induced by the LPV/r treatment is there is also a contribution of ritonavir. Likewise, since atazanavir is now also administered in association with ritonavir, the effects of this association in mice should be evaluated.
In conclusion, our results validated the use of mice as an experimental model to explore some aspects of the physiopathology of HAART-associated lipodystrophy in humans. In our experimental animal model, starting the treatment with adult mice seems a critical parameter to obtain reliable effects. In order to get a model closer to the human disease and to evidence additional clinical aspects relevant to HAART-associated lipodystrophy, it should be interesting to modify the treatment by increasing its duration and/or by adjusting the dose regimen to further approach human AUC . Alternatively, testing other PIs, alone or in association, could also reveal interesting clinical aspects. 
